title: Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
abstract: BACKGROUND
  The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS).
  
  
  RESULTS
  Among 559 lesions in 558 consecutive AMI from April 2003 to February 2006, the incidence of documented SAT after Cypher implantation (2/276 lesions, 0.72%) was almost the same as for BMS (2 cases, 0.71%). Aspirin (81-100 mg/day) plus ticlopidine (200 mg/day) were administered continuously after admission in all 4 cases.
  
  
  CONCLUSIONS
  Documented SAT did not increase after stenting with Cypher for AMI under aspirin plus ticlopidine.
authors.affiliation: Division of Cardiology, Saitama Prefecture Cardiovascular and Respiratory Center, Kohnan, Japan. ishikawa@jikei.ac.jp
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Mutoh
authors.forename: Yuji
authors.initials: Y
authors.lastname: Fuda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sakamoto
authors.forename: Hisayuki
authors.initials: H
authors.lastname: Okada
authors.forename: Michiaki
authors.initials: M
authors.lastname: Higashitani
authors.forename: Yousuke
authors.initials: Y
authors.lastname: Nakano
authors.forename: Junichi
authors.initials: J
authors.lastname: Yamaguchi
authors.forename: Kenji
authors.initials: K
authors.lastname: Enta
authors.forename: Takahiro
authors.initials: T
authors.lastname: Satoh
authors.forename: Kamon
authors.initials: K
authors.lastname: Imai
authors.forename: Toshinobu
authors.initials: T
authors.lastname: Horie
authors.forename: Seibu
authors.initials: S
authors.lastname: Mochizuki
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000150:complications; D003328:Coronary Thrombosis / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D018450:Disease Progression; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015994:Incidence; D008297:Male; D009203:Myocardial Infarction / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects*; D013988:Ticlopidine / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin; D020123:Sirolimus